3-10142041-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000551.4(VHL):c.194C>T(p.Ser65Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S65P) has been classified as Pathogenic.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.194C>T | p.Ser65Leu | missense_variant | Exon 1 of 3 | ENST00000256474.3 | NP_000542.1 | |
VHL | NM_001354723.2 | c.194C>T | p.Ser65Leu | missense_variant | Exon 1 of 3 | NP_001341652.1 | ||
VHL | NM_198156.3 | c.194C>T | p.Ser65Leu | missense_variant | Exon 1 of 2 | NP_937799.1 | ||
VHL | NR_176335.1 | n.264C>T | non_coding_transcript_exon_variant | Exon 1 of 4 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1Other:1
This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 65 of the VHL protein (p.Ser65Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of von Hippel-Lindau syndrome (PMID: 7987306, 10567493, 12114495, 22799452). This variant is also known as Ser136Leu. ClinVar contains an entry for this variant (Variation ID: 182975). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. Experimental studies have shown that this missense change affects VHL function (PMID: 15611064). This variant disrupts the p.Ser65 amino acid residue in VHL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7728151, 7987306, 22799452, 23384228). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Variant interpreted as Pathogenic and reported on 06-17-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.S65L pathogenic mutation (also known as c.194C>T), located in coding exon 1 of the VHL gene, results from a C to T substitution at nucleotide position 194. The serine at codon 65 is replaced by leucine, an amino acid with dissimilar properties. This variant has been observed in multiple individuals with a personal and/or family history that is consistent with von Hippel-Lindau (VHL) syndrome (Ambry internal data; Cybulski C et al. J Med Genet, 2002 Jul;39:E38; Skalova A et al. Pathol Res Pract, 2008 Apr;204:599-606; Dandanell M et al. BMC Med Genet, 2012 Jul;13:54; Hong B et al. Front Genet, 2019 Sep;10:867; Ayub N et al. Endocrinol Diabetes Metab Case Rep, 2022 Mar;2022). In an in vitro assay, a mutant S65L VHL protein demonstrated that while the mutant protein can still form the correct E3 protein complex, the complex completely lost the ability to bind and promote degradation of hypoxia-inducible transcription factor (Miller, F. J Biol Chem. 2005 Mar 4;280(9):7985-96). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Pancreatic cysts;C0730303:Retinal capillary hemangioma;C1332900:Cerebellar hemangioblastoma;C4024223:Spinal hemangioblastoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at